Page 2 - Visual Function News Today

The Centers for Medicare & Medicaid Services (CMS) has released the calendar year (CY) 2023 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC)...

National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.

A team of researchers have developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.

National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease

Research sheds light on severity for gene variants; establishes outcome measures for therapeutic trials.

Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to

Researchers at the National Eye Institute have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA).

Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations were given at the Retina Society 54 th Annual Scientific Meeting which took place September 29 October 2, 2021 in Chicago, IL. “These presentations demonstrate the targeted and ...

Scientists restore partial sight in blind man using optogenetic therapy Updated: Updated: May 25, 2021 12:58 IST During the tests, the patient was able to locate and touch a notebook on a table in front of him 92% of the time while wearing the goggles. Without them, he was unable to perform any visual task. Share Article AAA Experimental setup. Behavioral responses and brain activity were simultaneously recorded during the visual test. Credit: Sahel, JA., Boulanger-Scemama, E., Pagot, C. et al....

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision fo...